Nantahala Capital Management LLC Purchases 550,116 Shares of Savara Inc. $SVRA

Key Points

• Nantahala Capital Management LLC has increased its stake in Savara Inc. by 7.3%, now holding 8,075,375 shares valued at approximately $22.37 million, representing 0.9% of its investment portfolio.
• Insider Richard J. Hawkins purchased 48,225 shares of Savara, increasing his ownership by 71.72% to a total of 115,466 shares, valued at around $235,550.
• Analysts have mixed ratings on Savara's stock, with price targets ranging from $2.00 to $8.00, reflecting various expectations about the company's future performance.

Nantahala Capital Management LLC grew its stake in shares of Savara Inc. (NASDAQ:SVRA - Free Report) by 7.3% in the first quarter, according to its most recent disclosure with the SEC. The fund owned 8,075,375 shares of the company's stock after buying an additional 550,116 shares during the period. Savara makes up 0.9% of Nantahala Capital Management LLC's investment portfolio, making the stock its 15th biggest holding. Nantahala Capital Management LLC owned about 4.67% of Savara worth $22,369,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Ameriprise Financial Inc. acquired a new position in shares of Savara during the fourth quarter valued at about $37,000. Hsbc Holdings PLC bought a new position in Savara during the fourth quarter worth about $48,000. Brooklyn Investment Group bought a new position in Savara during the first quarter worth about $65,000. Y Intercept Hong Kong Ltd bought a new position in Savara during the first quarter worth about $74,000. Finally, Stonepine Capital Management LLC bought a new position in Savara during the first quarter worth about $81,000. Institutional investors and hedge funds own 87.93% of the company's stock.

Insider Transactions at Savara

In other Savara news, Director Richard J. Hawkins acquired 48,225 shares of Savara stock in a transaction on Friday, June 20th. The shares were purchased at an average cost of $2.04 per share, with a total value of $98,379.00. Following the completion of the purchase, the director owned 115,466 shares in the company, valued at $235,550.64. The trade was a 71.72% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 5.33% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on SVRA. Evercore ISI cut their price target on shares of Savara from $3.00 to $2.00 and set an "in-line" rating for the company in a research note on Wednesday, May 28th. Guggenheim reaffirmed a "buy" rating and set a $8.00 price objective (down previously from $9.00) on shares of Savara in a report on Wednesday, May 28th. HC Wainwright raised their price objective on shares of Savara from $5.00 to $8.00 and gave the stock a "buy" rating in a report on Wednesday. Wells Fargo & Company dropped their price objective on shares of Savara from $8.00 to $7.00 and set an "overweight" rating for the company in a report on Wednesday, May 28th. Finally, Oppenheimer raised their price objective on shares of Savara from $5.00 to $6.00 and gave the stock an "outperform" rating in a report on Friday, August 15th. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, Savara currently has an average rating of "Moderate Buy" and a consensus price target of $6.67.

Savara Trading Up 4.7%

SVRA stock traded up $0.16 during midday trading on Thursday, reaching $3.58. The company's stock had a trading volume of 1,775,465 shares, compared to its average volume of 1,278,540. Savara Inc. has a 52 week low of $1.89 and a 52 week high of $4.70. The stock has a market cap of $618.76 million, a PE ratio of -7.16 and a beta of 0.56. The company has a quick ratio of 11.08, a current ratio of 11.08 and a debt-to-equity ratio of 0.25. The business's 50-day simple moving average is $2.68 and its 200-day simple moving average is $2.70.

Savara (NASDAQ:SVRA - Get Free Report) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.02). As a group, sell-side analysts expect that Savara Inc. will post -0.45 EPS for the current year.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.